Literature DB >> 21034318

Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana).

Stephen J Divers1, Mark Papich, Michael McBride, Nancy L Stedman, David Perpinan, Thomas F Koch, Sonia M Hernandez, G Heather Barron, Melinda Pethel, Steven C Budsberg.   

Abstract

OBJECTIVE: To determine pharmacokinetics of meloxicam in healthy green iguanas following PO and IV administration and assess potential toxicity. ANIMALS: 21 healthy green iguanas (Iguana iguana). PROCEDURES: To assess pharmacokinetics, 13 iguanas were administered a single dose (0.2 mg/kg) of meloxicam PO and, 14 days later, the same dose IV. To assess potential toxicity, 4 iguanas were given meloxicam at a dosage of 1 or 5 mg/kg, PO, every 24 hours for 12 days, and results of histologic examination were compared with results for another 4 iguanas given a single dose of meloxicam (0.2 mg/kg).
RESULTS: There were no significant differences between PO and IV administration with regard to terminal half-life (mean ± SD, 12.96 ± 8.05 hours and 9.93 ± 4.92 hours, respectively), mean area under the curve to the last measured concentration (5.08 ± 1.62 μg•h/mL and 5.83 ± 2.49 μg•h/mL), volume of distribution (745 ± 475 mL/kg and 487 ± 266 mL/kg), or clearance (40.17 ± 10.35 mL/kg/h and 37.17 ± 16.08 mL/kg/h). Maximum plasma concentration was significantly greater following IV (0.63 ± 0.17 μg/mL) versus PO (0.19 ± 0.07 μg/mL) administration. Time from administration to maximum plasma concentration and mean residence time were significantly longer following PO versus IV administration. Daily administration of high doses (1 or 5 mg/kg) for 12 days did not induce any histologic changes in gastric, hepatic, or renal tissues. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that administration of meloxicam at a dose of 0.2 mg/kg IV or PO in green iguanas would result in plasma concentrations > 0.1 μg/mL for approximately 24 hours.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21034318     DOI: 10.2460/ajvr.71.11.1277

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

Review 1.  Analgesia for Sheep in Commercial Production: Where to Next?

Authors:  Alison Small; Andrew David Fisher; Caroline Lee; Ian Colditz
Journal:  Animals (Basel)       Date:  2021-04-14       Impact factor: 2.752

2.  Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice.

Authors:  Joelle C Ingrao; Ron Johnson; Elizabeth Tor; Yu Gu; Marcus Litman; Patricia V Turner
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-09       Impact factor: 1.232

3.  Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus).

Authors:  Laura Dhondt; Mathias Devreese; Siska Croubels; Siegrid De Baere; Roel Haesendonck; Tess Goessens; Ronette Gehring; Patrick De Backer; Gunther Antonissen
Journal:  Sci Rep       Date:  2017-09-25       Impact factor: 4.379

4.  A Critical Review on the Pharmacodynamics and Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs and Opioid Drugs Used in Reptiles.

Authors:  Allison Kah Yann Ting; Vanessa Shu Yu Tay; Hui Ting Chng; Shangzhe Xie
Journal:  Vet Anim Sci       Date:  2022-08-08

5.  Multi-Injection Pharmacokinetics of Meloxicam in Kemp's Ridley (Lepidochelys kempii) and Green (Chelonia mydas) Sea Turtles after Subcutaneous Administration.

Authors:  Terry M Norton; Tonya Clauss; Rachel Overmeyer; Stephanie Stowell; Michelle Kaylor; Sherry Cox
Journal:  Animals (Basel)       Date:  2021-12-10       Impact factor: 2.752

Review 6.  Pain and Pain Management in Sea Turtle and Herpetological Medicine: State of the Art.

Authors:  Ilenia Serinelli; Simona Soloperto; Olimpia R Lai
Journal:  Animals (Basel)       Date:  2022-03-10       Impact factor: 2.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.